Histopathologic And Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations

By sjmartinez • December 9, 2024

Seo YJ, Huston-Paterson HH, Schumm MA, Longstaff XR, Hughes EG, Tseng CH, Cheung DS, Yeh MW, Wu JX, Livhits MJ. Histopathologic And Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations. Endocr Pract. 2024 Dec 6:S1530-891X(24)00857-7. doi: 10.1016/j.eprac.2024.12.001. Epub ahead of print. PMID: 39647526.

Tags: BRAF V600E, Endocrinology, General Internal Medicine, molecular testing, Publications, RAS, recurrence, thyroid cancer

FXYD2 marks and regulates maturity of (beta) cells via ion channel-mediated signal transduction

Tacto C, Tahbaz M, Salib A, Wang S, Cayabyab F, Choi J, Kim K, Hamba Y, Perez H, Gershon PD, Damoiseaux R, Oh TG, Yoshihara[...]

Determining Insulin Pump Candidacy: The Disconnect Between Clinical Care Guidelines and Clinical Practice

Everett E, Dao L, Munaganuru N, Udeze K, Gutierrez S, Gann S, Meda A, Tiu R, Arevalo A, Drexler C, Abdulrahman Y, Santana C, Moin[...]

mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage

Verdejo HE, Parra V, Del Campo A, Vasquez-Trincado C, Gatica D, Lopez-Crisosto C, Kuzmicic J, Venegas-Zamora L, Zuñiga-Cuevas U, Troncoso MF, Troncoso R, Rothermel BA,[...]